Measured by its binding ability in a functional ELISA. When Siglec-2/CD22 Antibody (hL22 (Epratuzumab))-Chimeric is immobilized at 0.5 μg/mL (100 μL/well), Biotinylated Recombinant Human Siglec-2/CD22 His-tag Avi-tag binds with an ED50 of 0.3-2.4 ng/mL. Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. The ED50 for this effect is 0.1-0.8 μg/mL.